You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 1, January 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Macrophage Migration Inhibition Factor (MIF) in Drug Eruption

Sima Halevy, MD; Marcelo H. Grunwald, MD; Miriam Sandbank, MD; Bella Buimovice, MD; Henry Joshua, MD; Ella Livni, PhD

Arch Dermatol. 1990;126(1):48-51.


Abstract

• A controlled study was conducted to evaluate the macrophage migration inhibition factor test as a diagnostic aid in 50 patients with drug eruption. Two groups of patients served as controls: group A, 110 patients being treated with drugs without known cutaneous adverse reactions, and group B, 15 patients suffering from dermatologic disorders unrelated to drugs being taken. Positive macrophage migration inhibition factor responses were found toward a variety of drugs in 35 (70%) of the patients with drug eruptions, with no relation to the type of eruption or the duration of drug intake. The percentage of positive macrophage migration inhibition factor responses toward drugs in the patients with drug eruptions was higher than that in the two control groups (4.5% and 6.7%, respectively). The percentage of positive macrophage migration inhibition factor responses recorded for clinically "suspected" drugs was significantly higher than that recorded for the "nonsuspected" drugs.

(Arch Dermatol. 1990;126:48-51)



Author Affiliations

From the Department of Dermatology (Drs Halevy, Grunwald, and Sandbank), Emergency Room (Dr Buimovice), and Clinical Laboratory (Drs Joshua and Livni), Beilinson Medical Center, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Israel. Drs Halevy and Grunwald are now with the Department of Dermatology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.


Footnotes

Accepted for publication June 20, 1989.

Read in part before the 17th World Congress in Dermatology, Berlin, West Germany, May 29, 1987.

Reprint requests to Department of Dermatology, Soroka Medical Center, PO Box 151, Beer-Sheva 84101, Israel (Dr Halevy).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dermatologic Adverse Drug Reactions in a Family Medicine Setting
Ives et al.
Arch Fam Med 1992;1:241-245.
ABSTRACT  

Diagnosing Cutaneous Adverse Reactions to Drugs
Shear
Arch Dermatol 1990;126:94-97.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.